BliNK Biomedical Announces Close of Series A Funding

Jul 12, 2016

Lyon, France – BliNK Biomedical SAS (“BliNK”), a biopharmaceutical company focused on the discovery and development of novel therapeutic antibodies in oncology and immuno-oncology, is pleased to announce the closing of an additional €1.65 million investment by Idinvest Partners, bringing the total investment in its Series A round to €5.65 million.                                                                             

The additional funds announced today will be used to develop further the Company’s pipeline which comprises three innovative targets for in-house development, including a novel GPCR drug target made drugable by BliNK’s technology, and an attractive partnering opportunity.  

Jack Elands, Chief Executive Officer of BliNK Biomedical SAS, commented, “BliNK Biomedical welcomes the additional investment from Idinvest, as part of its support of the Company’s strategy to develop novel therapeutic antibodies with significant commercial potential in cancer indications. Using our extensively validated antibody discovery platform technology, combined with our excellent scientific advisory network, we are confident of realising the potential of our promising oncology and immuno-oncology pipeline.”

BliNK Biomedical’s suite of technologies allow deep mining of the B cell repertoire to discover unique antibodies by stimulating and amplifying B cells and directly detecting and retrieving single antigen specific B cells. This approach allows for the rapid identification and production of mAbs and has received extensive in-house and external validation including non-oncology programs with Sanofi Pasteur, GSK, Antidote and a leading veterinary company.

 

About BliNK Biomedical SAS

BliNK Biomedical is focused on the discovery and development of novel therapeutic antibodies with significant commercial potential in oncology and immuno-oncology. The Company has a suite of technologies to unlock otherwise intractable, but highly attractive targets, enabling a rich yield of high quality human antibodies isolated directly from B cells. This cutting edge technology, based on BliNK’s platforms (IVV, ISAAC and VIVA|Screen®), has been extensively validated in partnerships with big pharma and biotech in non-oncology indications. The Company has generated a pipeline comprising three innovative targets for in-house development and an attractive partnering opportunity. BliNK Biomedical is led by an experienced Board and is supported by a world-class scientific advisory network.

The Company is headquartered in Lyon (France) with a subsidiary, BliNK Therapeutics, in Stevenage (UK). Further information is available at www.blinkbiomedical.com and you can contact the Company at info@blinkbiomedical.com.

About Idinvest Partners

With more than €6 billion under management, Idinvest Partners is a leading pan-European private equity firm focused on the mid-market segment. Idinvest Partners has developed several complementary areas of expertise including investments in innovative European start-ups, primary, secondary and mezzanine investments in unlisted European companies, and private equity consulting. Founded under the name AGF Private Equity in 1997, Idinvest Partners was formerly part of Allianz until 2010 when it joined forces with IDI as an independent firm.

 

For more information, please contact:

 

BliNK Biomedical SAS
Jack Elands

 

 Tel: +33 6 38 35 70 08

 

 

Consilium Strategic Communications                    Chris Gardner / Sue Stuart /
Laura Thornton

 

Tel: +44 (0)20 3709 5700 blink@consilium-comms.com